Table 2.

Continuous venovenous hemodialysis^a

Patient no.	Sampling	DRT (h)	QD (ml/h, (mean ± SD))
7	First	40.5	1,500 ± 0
8	First	6	2,350 ± 122
9	First	19.5	2,083 ± 41
	Second	18.5	2,000 ± 0
10	First	−1	2,500 ± 0
	Second	39	2,500 ± 0
11	First	69.5/−1.5	2,400 ± 0
	Second	44/−9	2,400 ± 0
12	First	23.5	2,000 ± 0
13	First	23.5	2,000 ± 0
14	First	67/−11	2,500 ± 0

^aDRT, dialyzer running time, which is the time between start of continuous venovenous hemodialysis with the respective dialyzer and the start of the study caspofungin infusion. A DRT time of 0 means change of the dialyzer together with the start of caspofungin infusion. A negative dialyzer running time means that the dialyzer was changed during sampling. In patients 12 and 14, the dialyzer was changed once during the study. The maximum dialyzer running time was 72 h unless there was clotting of the dialyzer. Q_D, flow rate of dialysate (K2 by Fresenius) during the sampling. The amount of citrate applied for regional anticoagulation and the calcium dose for neutralization were guided by systemic and postfilter free calcium concentrations according to the manufacturer's guidelines. The blood flow rate was set to 80 to 120 ml/min. Interruptions of continuous renal replacement therapy during sampling, occurred because of diagnostic procedures such as CT scan or dialyzer clotting. For CRRT, a double-lumen dialysis catheter (Quinton Marhurkar or Joline) was inserted into a central vein. Patient 7 was first on CVVHD with regional citrate anticoagulation because of severe thrombocytopenia. Twenty-seven days later, on her second study day, she had been switched to CVVH because her thrombocytopenia had markedly improved. For CRRT, a double-lumen dialysis catheter (Quinton Marhurkar or Joline) was inserted into a central vein.